A new device to prop open heart arteries after interventions to unclog them adapts over time to allow restoration of the ...

Elixir Medical's DynamX bioadaptor, introduced as a potential game-changer in heart artery treatments, adapts over time to restore the artery's natural motion. A study showed it leads to fewer ...

The third-quarter earnings season was at its peak this week for large drugmakers, with several companies — Eli Lilly LLY, Merck MRK, Pfizer PFE, AbbVie ABBV and Novartis NVS — announcing their results ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

A new survey shows that three Big Pharmas have stolen the hearts of patient groups representing nearly 1 million people with cardiovascular conditions. | A new survey shows that three Big Pharmas have ...

The company's key products, including Verzenio for cancer and Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin ...

Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabetes.

While dapagliflozin (Farxiga) and empagliflozin (Jardiance) are approved for CKD in adults at risk of progression -- an ...

Mounjaro sales more than doubled to $3.11 billion from $1.41 billion a year ago. The U.S. pharma giant reported third-quarter ...

On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...

While dapagliflozin (Farxiga) and empagliflozin (Jardiance) are approved for CKD in adults at risk of progression -- an ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...